Thermal Ablation of Renal Cell Carcinoma in Patients With Morbid Obesity : Assessment of Technique, Safety, and Oncologic Outcomes

BACKGROUND. Obesity is a worldwide problem that impacts patient health as well as the morbidity associated with surgical procedures. Thus, patients with morbid obesity may not be suitable candidates for curative surgery. For this patient population, thermal ablation may be an effective alternative to nephrectomy. OBJECTIVE. The purpose of this study was to determine the feasibility, oncologic outcomes, and survival of patients with morbid obesity and renal cell carcinoma treated with thermal ablation. MATERIALS AND METHODS. A retrospective analysis was performed of 107 patients treated with CT-guided renal ablation for clinical T1 renal cell carcinoma between February 2005 and December 2017. Patients were stratified into two cohorts on body mass index of ≥ 40 kg/m2 (morbidly obese) and body mass index (weight in kilograms divided by the square of height in meters) of ≥ 40 (morbidly obese) and 18.5-24.9 (normal weight). Anesthetic and radiation dosages, procedure time, residual disease, and local recurrence, and adverse events were analyzed between the two groups. Kaplan-Meier statistics were used to evaluate cancer-related outcomes for each group. RESULTS. Thirty-four patients were morbidly obese, and 73 patients had normal weight. Morbid obesity was associated with longer procedural duration (p = .001), sedative doses (p = .002) and radiation exposure (p = .001) than normal weight. Hematomas were more prevalent in patients with morbid obesity than in those of normal weight (p = .01), but treatment efficacy and local recurrences were comparable with those for normal-weight individuals (p = .81 and p = .12, respectively). Cancer-related outcomes were equivalent between the two groups based on 5 years of imaging observation data. CONCLUSION. CT-guided thermal ablation remains technically feasible, well-tolerated, and effective in patients with morbid obesity and renal cell carcinoma, with the caveat of increased risk of perinephric hematoma, anesthesia dose, and radiation exposure. CLINICAL IMPACT. CT-guided thermal ablation can be considered a safe and effective treatment for renal cell carcinoma in patients with morbid obesity.

Errataetall:

CommentIn: AJR Am J Roentgenol. 2020 Aug 19;:. - PMID 32812802

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:216

Enthalten in:

AJR. American journal of roentgenology - 216(2021), 4 vom: 19. Apr., Seite 989-996

Sprache:

Englisch

Beteiligte Personen:

Zhou, Wenhui [VerfasserIn]
Herwald, Sanna E [VerfasserIn]
Uppot, Raul N [VerfasserIn]
Arellano, Ronald S [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
Morbid obesity
Renal cell carcinoma
Thermal ablation
Treatment outcome

Anmerkungen:

Date Completed 14.04.2021

Date Revised 14.04.2021

published: Print-Electronic

CommentIn: AJR Am J Roentgenol. 2020 Aug 19;:. - PMID 32812802

Citation Status MEDLINE

doi:

10.2214/AJR.20.23803

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM313304181